Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 10/6/2025

Hives from Amoxicillin: Type 1 Hypersensitivity and Cefdinir Avoidance

Understanding the Allergy Classification

  • Hives occurring within hours of amoxicillin exposure constitute an immediate-type hypersensitivity reaction, which is IgE-mediated (Type 1 hypersensitivity) 1, 2

Why Cefdinir Must Be Avoided

  • Cefdinir is an amino-cephalosporin that shares an identical or highly similar R1 side chain with amoxicillin, making cross-reactivity the primary concern rather than the beta-lactam ring itself 2, 4

Cross-Reactivity Risk Data

  • Amino-cephalosporins (including cefdinir) have a cross-reactivity rate with penicillins when side chains are identical, ranging from 12.9% to 14.5% for cephalosporins available in clinical practice with similar side chains to amoxicillin 1, 2, 3
  • This risk applies to both immediate-type (IgE-mediated) and delayed-type (T-cell mediated) penicillin allergies 2, 3

Algorithmic Approach to Cephalosporin Selection

  • If a reaction occurred <5 years ago, avoid all penicillins and cephalosporins with similar side chains (cefdinir, cephalexin, cefaclor, cefamandole) 1, 2, 5
  • Safe alternatives include cefazolin, ceftriaxone, cefpodoxime, and cefuroxime, which have dissimilar side chains and <2% cross-reactivity 1, 2, 6
  • Carbapenems or aztreonam are also safe options with no cross-reactivity 1, 2

Practical Recommendations

  • For a patient with hives from amoxicillin, document this as "immediate-type penicillin allergy" and absolutely avoid all penicillins, cefdinir, cephalexin, cefaclor, and cefamandole 1, 2, 5
  • Safe first-line alternatives include cefazolin, ceftriaxone, cefuroxime, and cefpodoxime 1, 2, 6
  • The safest options with zero cross-reactivity are carbapenems (meropenem, ertapenem) or aztreonam 1, 2

When Skin Testing is Unavailable

  • The Dutch guideline (2023) provides the most current evidence-based approach: avoid similar side-chain cephalosporins entirely rather than attempting empiric dosing 1, 2, 3
  • The risk of a severe reaction (up to 16.45%) outweighs the convenience of using cefdinir 2, 3